The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

The US Food and Drug Administration (FDA) has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to Actemra, developed by South ...

Autoimmune disorders in children can cause symptoms often mistaken for common childhood illnesses. More precise diagnoses and ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

Biologic therapy reduces TMJ inflammation in children with juvenile arthritis, according to a new study. Findings show ...

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...